A Meta-Analysis of Efficacy and Safety of PD-1/PD-L1 Inhibitors in Triple-Negative Breast Cancer

Table 1

Basic information of the enrolled literature.

Author	Year	Phase	Patient	Arm 1	Arm 2	Patients
						Total	PD-L1 negative	PD-L1 positive	Outcomes
Bachelot et al. [15]	2021	II	TNBC	Durvalumab	Maintenance chemotherapy	82	32	29	OS, PFS, AEs
Brufsky et al. [16]	2021	II	mTNBC	Cobimetinib	Placebo + paclitaxel	62	44	18	OS, PFS, AEs
Cortes et al. [17]	2020	III	mTNBC	Pembrolizumab	Placebo + chemotherapy	847	—	—	PFS, AEs
Emens et al. [18]	2021	III	TNBC	Atezolizumab	Placebo + nab-paclitaxel	902	533	369	OS, PFS, AEs
Miles et al.[19]	2021	III	mTNBC	Atezolizumab	Placebo + paclitaxel	651	293	358	PFS, OS, AEs
Schmid et al. [20]	2020	III	Stage II/III TNBC	Pembrolizumab	Placebo	1174	973	196	PFS, AEs
Winer et al. [21]	2021	III	mTNBC	Pembrolizumab	Chemotherapy	622	217	405	OS, PFS, AEs

TNBC: triple-negative breast cancer; PD: progression death; OS: overall survival; PFS: progression-free survival; AEs: adverse events.